Baird Maintains Outperform on GRAIL, Raises Price Target to $118
9/22/2026
Impact: 80
Healthcare
Baird analyst Catherine Schulte has maintained an 'Outperform' rating on GRAIL (NASDAQ: GRAL) and increased the price target from $96 to $118. This adjustment reflects a positive outlook on the company's performance.
AI summary, not financial advice
Share: